KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) ---- Continuing enrollment ...